Ultrasonic evaluation MAFLD in screening severety matabolic disorders

Abstract

Metabolic dysfunction associated fatty liver disease (MAFLD) is a new proposed term for non-alcoholic fatty liver disease (NAFLD). a liver steatosis associated with Type 2 diabetes mellitus or increased physical weight/thickness, or with two or more metabolic disorders. This indicates metabolic abnormalities that result in fat accumulation in hepatocytes without the presence of alcoholic liver disease or other causes that would lead to hepatocyte abnormalities. Our goal was determine the correlation between certain stages of fatty liver disease determined by ultrasonography with increased body weight/obesity, diabetes mellitus and other metabolic disorders and with the values of biochemical parameters of liver enzymes. A prospective study was conducted at the public health institution Zivinice Health Center from August 2022 until January 2024 on a random sample of 101 patients. Observing the entire examined group, a difference in the gender distribution of hepatic steatosis is noticed, and graphically it is shown that men have hepatic steatosis more often than women. In fatty liver disease (MAFLD), stage G2 was most prevalent in 32% of patients. Ultrasonography, along with clinical and biochemical indicators, should be an integral part of screening and monitoring of metabolic disorders as it is a non-invasive and easily accessible imaging method and allows timely therapeutic action and prevention of hepatic and extrahepatic complications.